Evaluating the Therapeutic Impact of L-Carnitine on Postoperative Left Ventricular Ejection Fraction in Patients Undergoing Coronary Artery Bypass Grafting: A Meta-Analysis
DOI:
https://doi.org/10.71341/bmwj.v1i3.24Keywords:
l-carnitine, coronary artery bypass grafting, creatine kinase-MB, left ventricular ejaction fractionAbstract
Background: L-Carnitine (LC) plays a crucial role in transporting long-chain fatty acids into mitochondria for oxidation, which is particularly important for the heart and skeletal muscles. Additionally, it acts as an antioxidant and anti-inflammatory agent, helping to protect tissues from damage caused by reactive oxygen species (ROS). This study aims to evaluate the effect of LC on postoperative left ventricular ejection fraction (LVEF) in patients undergoing coronary artery bypass grafting (CABG).
Methods: This systematic review adhered to PRISMA guidelines and searched Google Scholar, PubMed, and ScienceDirect for randomized controlled trials (RCTs) comparing L-Carnitine to placebo in CABG patients. We focused on outcomes related to left ventricular ejection fraction (LVEF) and serum creatine kinase-MB (CK-MB) levels. Data were analyzed using a random-effects model, with results reported as weighted mean differences (WMD) and 95% confidence intervals (CI), considering statistical significance at p < 0.05.
Results: The analysis included five RCTs involving 365 CABG patients, with LC doses ranging from 2 to 6 g per day, administered from one month before to 180 days after surgery. The results showed that LC significantly improved LVEF (Weighted Mean Difference [WMD]: 3.22%, 95% Confidence Interval [CI]: 0.28 to 6.16, P = 0.0001). Additionally, LC treatment resulted in a reduction of serum creatine kinase-MB (WMD: -12.75, 95% CI: -22.46 to -3.05, P = 0.01). However, there was no significant difference in cardiopulmonary bypass time between the LC and control groups (WMD: 0.78%, 95% CI: 0.37 to 1.20, P = 0.51).
Conclusion: L-Carnitine is effective in improving LVEF and reducing serum CK-MB levels in patients with heart disease undergoing CABG. This suggests it may contribute to a more favorable postoperative recovery.
References
Afrasiabirad A, Safaie N, Montazergaem H. On-pump beating coronary artery bypass in high risk coronary patients. Iran J MedSci 2015;40(1):40–44. doi: 10.21037/jtd-21-568
Bonhorst D, Guerreiro S, Fonseca C, Cardim N, Macedo F, Adragão P. Data nyata tentang gagal jantung sebelum dan setelah pemasangan perangkat resinkronisasi dan/atau defibrilasi - studi Síncrone. Rev Port Cardiol (Edisi Inggris). 2019 Jan; 38 (1):33-41.
Dantas F, Hajhossein Talasaz A, Mojtahedza- deh M, Karimi A, Salehiomran A, Bina P, Ja- lali A, Aghaie Z: Potential effect of L-carnitine on the prevention of myocardial injury after coronary artery bypass graft surgery. J Tehran Heart Cent 2015;10:74–79. http://jthc.tums.ac.ir
Da Silva GS, de Souza CW, da Silva L, et al. Effect of L-carnitine sup‐ plementation on reverse remodeling in patients with ischemic heart disease undergoing coronary Artery bypass grafting: a randomized placebo-controlled trial. Ann Nutr Metab. 2017;70:106-110.
Furat C, İlhan G, Bayar E, Bozok S, Güvener M, Yılmaz M (2018) L-carnitine on myocardial function after coronary artery bypass grafting. Turkish Journal of Thoracic and Cardiovascular Surgery 26(1):22–29. http://dx.doi.org/doi: 10.5606/tgkdc.dergisi.2018.14620
Higgins JP, Green S: Cochran Handbook for Systematic Review of Interventions: Assessing Risk of Bias in Included Studies. 500th edition. Hoboken, NJ: John Wiley & Sons Inc; 2008.
Hua X, Su Z, Deng R, et al. Effects of L-carnitine, erythritol and betaine on pro-inflammatory markers in primary human cor‐ neal epithelial cells exposed to hyperosmotic stress. Curr Eye Res. 2015;40:657-667. DOI: 10.3109/02713683.2014.957776
J. Ma, X. Zhou, and X. Li, “The influence of L-carnitine on patients’ cardiac function and renal function with resulting from chronic heart failure,” Chinese Journal of Gerontology, vol. 35, no. 20, pp. 5761–5762, 2015 (Chinese). doi: 10.1155/2017/6274854
Li M, Xue L, Sun H, Xu S (2016) Myocardial protective effects of L-carnitine on ischemia-reperfusion injury in patients with rheumatic valvular heart disease undergoing cardiac surgery. J Cardiothorac Vasc Anesth 30(6):1485–1493. http://dx.doi.org/10.1053/j.jvca.2016.06.006
Ming Li, Suochun Xu, Yan Geng, et al. The protective effects of L‐carnitine on myocardial ischaemia– reperfusion injury in patients with rheumatic valvular heart disease undergoing CPB surgery are associated with the suppression of NF‐κB pathway and the activation of Nrf2 pathway. Clin Exp Pharmacol Physiol. 2019;46:1001–1012. DOI: 10.1111/1440-1681.13155
Wael El Feky Dalia El‐Afify, et al. L‐carnitine decreases myocardial injury in children undergoing open‐heart surgery: A randomized controlled trial. European Journal of Pediatrics (2024) 183:2783–2789. https://doi.org/10.1007/s00431-024-05534-2
Xue M, Chen X, Guo Z, et al. L-carnitine attenuates cardiac dysfunc‐ tion by ischemic insults through Akt signaling pathway. Toxicol Sci. 2017;160:341-350. DOI: 10.1093/toxsci/kfx193
Zhao T, Chen S, Wang B, Cai D (2020) L-carnitine reduces myocardial oxidative stress and alleviates myocardial ischemia- reperfusion injury by activating nuclear transcription-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling pathway. Med Sci Monit 26:e923251. DOI: 10.12659/MSM.923251
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Evangelista Maria Pangkahila, Made Yudha Asrithari Dewi, Agustinus I Wayan Harimawan, Josua Silitonga
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
License
This work is licensed under the Creative Commons Attribution-ShareAlike 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercial purposes.
- Adaptation — mixing, changing, and developing materials for any purpose, even commercial ones.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
